French drugmaker Sanofi has confirmed its plan to spend €1.3bn on an insulin factory at its site near Frankfurt, website BioProcess International reports.
The 36,000-sq-m plant will replace a previous production facility on the site, and is set to begin operations in 2029.
“We are reaffirming our commitment to diabetes patients worldwide and utilising the many years of expertise at our Höchst BioCampus with its highly qualified employees,” said Brendan O’Callaghan, chairman of the company’s supervisory board in Germany.
The company supplies patients in 80 countries with 20 insulin products and employs over 4,000 staff.
Sanofi’s plans were provisionally announced at the start of July.
The Frankfurt-Höchst site is one of its largest, with around 6,600 employees. It produces the long-established diabetes drug Lantus. The plant is being supported by subsidies from the German federal government, the Hessian state government and the city of Frankfurt, and is subject to approval by the European Commission.
The post France’s Sanofi to build €1.3bn insulin plant in Germany appeared first on Global Construction Review.
